Evaxion Biotech A/S Profit Margin

Evaxion Biotech A/S's profit margin stands at -115.59% as of June 2026. That compares with -376.11% in the prior-year period — up 69.3% year over year. That is below the Healthcare sector average of 13.89%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Evaxion Biotech A/S reported -115.59% in profit margin versus -376.11% a year earlier — a 69.3% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

Evaxion Biotech A/S sits lower the Healthcare benchmark (13.89%) with a profit margin of -115.59%. That is roughly 932.0% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A profit margin of -115.59% for Evaxion Biotech A/S means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how Evaxion Biotech A/S's profit margin evolved across reporting periods, while the comparison chart places EVAX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.